Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 9Phase 3 3Phase 1/2 3Phase 4 1Phase 2/3 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 120Carboplatin 114Pemetrexed 74Cisplatin 71Nivolumab 68Paclitaxel 58Docetaxel 56Radiotherapy 41Erlotinib Hydrochloride 41Gemcitabine 35Etoposide 34atezolizumab 30osimertinib 29Cetuximab 27Ipilimumab 25Bevacizumab 25Radiosurgery 22durvalumab 21Cyclophosphamide 20Drug Therapy 18130-nm albumin-bound paclitaxel 17avelumab 14Taxes 14Gefitinib 14Albumin-Bound Paclitaxel 14Irinotecan 13Injections 13fludarabine 11Radiation 11cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × nintedanib × Thoracic × Clear all
NCT03377023 2026-04-02

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
66 enrolled 17 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

China Medical University Hospital

Phase 1/2 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03361319 2020-11-24

N3

Royal Marsden NHS Foundation Trust

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡